Skip to main content

Esperion Therapeutics, Inc. (ESPR)

NASDAQ: ESPR · IEX Real-Time Price · USD
+0.04 (0.51%)
After-hours:Oct 25, 2021 7:33 PM EDT
-1.00 (-11.38%)
At close: Oct 25, 4:00 PM
Market Cap208.77M
Revenue (ttm)62.11M
Net Income (ttm)-324.52M
Shares Out26.23M
EPS (ttm)-12.14
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close8.79
Day's Range7.74 - 8.56
52-Week Range7.74 - 39.49
Price Target25.09 (+222.1%)
Est. Earnings DateNov 2, 2021

About ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to...

IPO DateJun 26, 2013
CEOTimothy Mayleben
Stock ExchangeNASDAQ
Ticker SymbolESPR
Full Company Profile

Financial Performance

In 2020, ESPR's revenue was $227.55 million, an increase of 53.37% compared to the previous year's $148.36 million. Losses were -$143.55 million, 47.7% more than in 2019.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is 25.09, which is an increase of 222.08% from the latest price.

Price Target
(222.08% upside)
Analyst Consensus: Buy


Why Esperion Therapeutics Plummeted by 11% Today

Shareholders were displeased with the company's latest financial move.

7 hours ago - The Motley Fool

Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure

Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.

6 days ago - Zacks Investment Research

Esperion Chops 40% Workforce As Launch Of Cholesterol Medication Falters

Esperion Therapeutics Inc's (NASDAQ: ESPR) cholesterol drug marketing strategy has soured badly, as it has been struggling to sell its heart disease pill for more than a year. What Happened: The Company...

1 week ago - Benzinga

ESPERION Announces Plan for Transformative Long-Term Growth

– Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial –

1 week ago - GlobeNewsWire

ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholest...

ANN ARBOR, Mich., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the lipid management company, today announced that it will host an investor webinar on the current landscape and future dire...

1 month ago - GlobeNewsWire

Esperion Therapeutics (ESPR) Down 5.9% Since Last Earnings Report: Can It Rebound?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Esperion to Participate in Upcoming Virtual Investor Conference

ANN ARBOR, Mich., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that members of Esperion's management team will participate in the upcoming Morgan Stanley 19th Annual Global ...

1 month ago - GlobeNewsWire

Esperion (ESPR) Q2 Loss Narrower Than Expected, Drug Price Up

Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings but misses the same for sales. Stock down.

2 months ago - Zacks Investment Research

Esperion Therapeutics (ESPR) Reports Q2 Loss, Misses Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 8.24% and -1.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Recap: Esperion Therapeutics Q2 Earnings

Shares of Esperion Therapeutics (NASDAQ:ESPR) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were down 138.66% over the past year to ($1.67), which beat ...

2 months ago - Benzinga

ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update

– U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew 67% Sequentially to $10.6 Million ––  Growth Driven by Increase in Demand and S...

2 months ago - GlobeNewsWire

Earnings Preview: Esperion Therapeutics (ESPR) Q2 Earnings Expected to Decline

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Esperion to Report Second Quarter 2021 Financial Results August 3, 2021

ANN ARBOR, Mich., July 13, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2021 financial results before the open of the U.S. financial markets on Tuesday...

3 months ago - GlobeNewsWire

7 Names That Could Be The Next Short-Squeeze Stocks

Many investors are taking advantage of short-squeeze stocks by buying heavily shorted stocks when trading at or near all-time lows. The post 7 Names That Could Be The Next Short-Squeeze Stocks appeared ...

3 months ago - InvestorPlace

12 Most Highly Shorted Stocks Heading Into Q3 2021

Investors are seeking out the most highly shorted stocks. With GME and AMC seeing monolithic gains, can the same thing be done elsewhere?

3 months ago - InvestorPlace

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., July 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on June 28, 2021, the Compensation Committee of Esperion's Board of Directors granted 31 new employees (...

3 months ago - GlobeNewsWire

Esperion Shorts Have Cleaned Up

Short-sellers who made a bet on Esperion Therapeutics Inc. ( ESPR , Financial) have done well during the past year, but is it time to cash out? While Experion's share price has been cut nearly $30 to ab...

3 months ago - GuruFocus

ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer

– Expansion of management team with proven leader in cardiovascular disease supports advancement of CLEAR Outcomes trial and ESPERION therapeutic pipeline – – Expansion of management team with proven le...

3 months ago - GlobeNewsWire

Why Is Esperion Therapeutics (ESPR) Up 6.4% Since Last Earnings Report?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

8 Stocks With The Highest Short Interest

Traders often look at short interest to get a sense of how many people are bearish on a stock and how strong the possibility of a short squeeze is. But simply looking at the size of the outstanding shor...

4 months ago - Benzinga

Esperion to Participate in Two Upcoming Virtual Investor Conferences

ANN ARBOR, Mich., May 24, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of J...

5 months ago - GlobeNewsWire

ESPERION Appoints Sheldon Koenig as President and CEO

-- Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space;  previously served as ESPERION COO -- -- Succeeds Tim Mayleben, who served as P...

5 months ago - GlobeNewsWire

Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet's Potential to Lower Ab...

- Patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statins and treated with NEXLETOL predicted to experience a 3.3% further absolute reduction in 10-year cardiovascula...

5 months ago - GlobeNewsWire

Why Esperion Therapeutics Plummeted Nearly 22% Today

It was all about the earnings.

5 months ago - The Motley Fool

Esperion Stock Plummets On Wider Than Expected Q1 Earnings Loss; Analysts Move To Sidelines

Esperion Therapeutics Inc (NASDAQ: ESPR) reported a first-quarter EPS loss of $3.50, compared to $2.84 a year ago, which missed the analyst consensus estimate of $2.52. The company reported quarterly sa...

5 months ago - Benzinga